Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof

A kind of cell, NK cell technology, applied in the field of immunology

Pending Publication Date: 2020-03-17
埃克苏马生物技术公司
View PDF30 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These relatively long ex vivo expansion times create issues with cell viability and sterility, as well as sample consistency issues including expandability challenges

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
  • Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
  • Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0099] The present invention overcomes the challenges of the prior art by providing improved methods and compositions for genetically modifying lymphocytes, such as NK cells, and in illustrative embodiments T cells. For example, some of these methods do not include preactivating lymphocytes, and some of these methods are performed in less time than previous methods. Additionally, compositions are provided that have many uses, including their use in these improved methods. Some of these compositions are genetically modified lymphocytes with improved proliferation and survival qualities, including when cultured in vitro, eg, in the absence of growth factors. These genetically modified lymphocytes will have uses such as: as a research tool to better understand the factors that affect T cell proliferation and survival; Production of factors such as growth factors and immunomodulators.

[0100] Some embodiments provided herein are methods for performing adoptive cell therapy comp...

Embodiment 1

[1199] Example 1. Generation of riboswitches specifically responsive to nucleoside analog antiviral drugs.

[1200] This example provides a method for screening libraries based on natural structural riboswitches that bind guanosine and deoxyguanosine. These riboswitches are used as a framework to develop a biased library for selection of aptamers that specifically bind ligand nucleoside analogs. Previously, isothermal titration calorimetry has been used to show that these natural riboswitches bind to their natural ligands. Additional testing revealed that the deoxyguanosine switch also weakly interacts with nucleoside analogs (acyclovir and penciclovir), leading to the redesign of this sequence into a new library. The single-stranded region of the riboswitch is used to specifically respond to selected mutations and variant sequences of acyclovir or penciclovir.

[1201] Material

[1202] Order selected components from Sigma-Aldrich (St. Louis, MO): Guanine, Guanosine, Deoxy...

Embodiment 2

[1233] Example 2. Isolation of conditional scFv's

[1234]The pool of potential splice sites was removed, and tumor antigen-specific scFv's were synthesized using overlapping oligomeric synthesis and cloned into a CAR shuttle construct containing an acyclovir responsive component and a primate CD3ζ promoter. As initial prototypes, anti-ECD of EPCAM or ERBB2 scFv with CD8-α signal peptide, stalk and transmembrane domain were utilized. Solid tumor microenvironment-restricted CAR products were generated using methods as described in US Patent No. 8,709,755 and PCT Publication No. WO / 2016 / 033331A1 or by direct selection from human phage libraries under licensed and non-licensed conditions. Briefly, human V from Creative Biolabs (Shirley, New York) was panned under the following tumor license conditions H ×V L Libraries: 100 μg / ml hyaluronic acid, 100 kDa fragments (Lifecore Biomedical, Chasca, MN), 20 mg / ml recombinant HAS (Cyagen, Santa Clara, CA), 200 ng / ml recombinant human V...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and / or NK cells. The methods can include inhibitory RNA molecule(s) and / or engineered signaling polypeptides that can include a lymphoproliferative element, and / or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and / or genetically modified T cells and / or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and / or pH-modulating agents.

Description

[0001] Cross References to Related Applications [0002] This application is a continuation-in-part of International Application No. PCT / US2017 / 023112, filed March 19, 2017; a continuation-in-part of International Application No. PCT / US2017 / 041277, filed July 8, 2017; Continuation-in-Part of U.S. Application No. 15 / 462,855, filed March 19; and Continuation-in-Part of U.S. Application No. 15 / 644,778, filed July 8, 2017; and claiming interest in: March 2017 U.S. Provisional Application No. 62 / 467,039, filed September 3; U.S. Provisional Application No. 62 / 560,176, filed September 18, 2017; U.S. Provisional Application No. 62 / 564,253, filed September 27, 2017; and 2017 U.S. Provisional Application No. 62 / 564,991, filed September 28; International Application No. PCT / US2017 / 023112 asserting U.S. Provisional Application No. 62 / 390,093, filed March 19, 2016, filed July 8, 2016 U.S. Provisional Application No. 62 / 360,041 and U.S. Provisional Application No. 62 / 467,039, filed March 3, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/10C12N15/867C12N5/0783C12N5/10C07K14/725C07K14/705C07K14/715A61K48/00C12N15/86
CPCC07K14/705C12N5/0636C12N5/0646C12N15/1048C12N15/86C12N2740/16043C12N2740/16052C07K14/54C07K14/5418C07K14/70596C07K14/7155C07K2319/035C07K2319/30C12N2510/00C07K2319/00C12N2501/2302C12N2501/2307C12N2502/99C12N2740/16045C12N2830/001C12N2830/007A61K39/464412A61K39/4631A61K39/4611
Inventor 格雷戈里·伊恩·弗罗斯特詹姆斯·约瑟夫·奥努弗吉亚贝·H·古比加法扎德·哈里扎德
Owner 埃克苏马生物技术公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com